申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
公开号:US06093723A1
公开(公告)日:2000-07-25
This invention relates to 4-substituted .beta.-carbolines and .beta.-carboline analogs that inhibit Ca.sup.+2 influx and interleukin-2 (IL-2) production. The 4-substituted .beta.-carbolines and .beta.-carboline analogs of this invention are represented by formula (I): ##STR1## wherein Q, n, R, R', R" and R.sub.1 -R.sub.4 are as defined herein. This invention also relates to methods for producing .beta.-carbolines. Because of their selective immunomodulating properties, the compounds and pharmaceutical compositions of this invention are particularly well suited for preventing and treating immune disorders, including autoimmune disease, inflammatory disease, organ transplant rejection and other disorders associated with IL-2 mediated immune response.
本发明涉及4-取代β-咔唑和β-咔唑类似物,可抑制Ca2+通量和白细胞介素-2(IL-2)的产生。本发明的4-取代β-咔唑和β-咔唑类似物由式(I)表示:其中Q,n,R,R',R"和R1-R4如本文所定义。本发明还涉及制备β-咔唑的方法。由于其选择性免疫调节特性,本发明的化合物和制药组合物特别适用于预防和治疗免疫疾病,包括自身免疫性疾病、炎症性疾病、器官移植排斥和与IL-2介导的免疫反应有关的其他疾病。